FDA warns ImmunityBio on promotions
What happened
The FDA issued a formal objection to ImmunityBio for promotional content — including a podcast and TV ad — saying risk information was omitted or minimised and efficacy/mechanism claims were overstated. The agency also noted the podcast should have been submitted as promotional material, underscoring that non‑traditional channels are now squarely within promotional-review requirements. (mmm-online.com)
Why it matters
The FDA posted a formal warning letter to ImmunityBio dated March 13, 2026 that names the company’s CEO, Richard Adcock, and calls out a broadcast television spot plus a podcast episode as the communications under review. (fda.gov) The agency’s letter notes the podcast episode aired January 19, 2026 on The Sean Spicer Show and featured ImmunityBio Executive Chairman Patrick Soon‑Shiong, and it expressly states the podcast was not submitted to FDA at the time of initial dissemination as required by regulation. (fda.gov) The regulatory point the OPDP emphasized is procedural as well as substantive: drugmakers must treat longform audio and other non‑traditional channels as promotional material when they include product claims, and those materials generally must be submitted (using Form FDA‑2253) at initial dissemination under 21 CFR 314.81(b)(3)(i) so the agency can review consistency with approved labeling. (fda.gov) The letter reiterates the approved scope of Anktiva: treatment in combination with Bacillus Calmette‑Guérin (BCG) for adult patients with BCG‑unresponsive non‑muscle‑invasive bladder cancer with carcinoma in situ — a specific, limited indication, not a broad anti‑cancer claim. (fda.gov) The FDA also references prior Office of Prescription Drug Promotion communications to ImmunityBio’s subsidiary (Altor BioScience) on September 9, 2025 and January 7, 2026 that flagged website efficacy claims — for example, website text citing “84% cystectomy‑free at 36 months” and “99% disease‑specific overall survival at 36 months” — and the agency said the single‑arm QUILT‑3.032 study cited on those pages was not capable of supporting those time‑to‑event efficacy conclusions. (fda.gov) Operational actions the FDA requested are specific and time‑bound: the warning letter directs ImmunityBio to cease or take down the challenged communications where appropriate and to submit a written response addressing FDA’s concerns within 15 working days of receipt. (fda.gov) The market and legal fallout has been immediate: shares fell sharply after the letter became public and multiple law firms have announced investigations and suits tied to the promotional claims. (finance.yahoo.com)
Key numbers
- (mmm-online.com) The FDA posted a formal warning letter to ImmunityBio dated March 13, 2026 that names the company’s CEO, Richard Adcock, and calls out a broadcast television spot plus a podcast episode as the communications under review.
Quick answers
What happened in FDA warns ImmunityBio on promotions?
The FDA issued a formal objection to ImmunityBio for promotional content — including a podcast and TV ad — saying risk information was omitted or minimised and efficacy/mechanism claims were overstated. The agency also noted the podcast should have been submitted as promotional material, underscoring that non‑traditional channels are now squarely within promotional-review requirements. (mmm-online.com)
Why does FDA warns ImmunityBio on promotions matter?
The FDA posted a formal warning letter to ImmunityBio dated March 13, 2026 that names the company’s CEO, Richard Adcock, and calls out a broadcast television spot plus a podcast episode as the communications under review. (fda.gov) The agency’s letter notes the podcast episode aired January 19, 2026 on The Sean Spicer Show and featured ImmunityBio Executive Chairman Patrick Soon‑Shiong, and it expressly states the podcast was not submitted to FDA at the time of initial dissemination as required by regulation. (fda.gov) The regulatory point the OPDP emphasized is procedural as well as substantive: drugmakers must treat longform audio and other non‑traditional channels as promotional material when they include product claims, and those materials generally must be submitted (using Form FDA‑2253) at initial dissemination under 21 CFR 314.81(b)(3)(i) so the agency can review consistency with approved labeling. (fda.gov) The letter reiterates the approved scope of Anktiva: treatment in combination with Bacillus Calmette‑Guérin (BCG) for adult patients with BCG‑unresponsive non‑muscle‑invasive bladder cancer with carcinoma in situ — a specific, limited indication, not a broad anti‑cancer claim. (fda.gov) The FDA also references prior Office of Prescription Drug Promotion communications to ImmunityBio’s subsidiary (Altor BioScience) on September 9, 2025 and January 7, 2026 that flagged website efficacy claims — for example, website text citing “84% cystectomy‑free at 36 months” and “99% disease‑specific overall survival at 36 months” — and the agency said the single‑arm QUILT‑3.032 study cited on those pages was not capable of supporting those time‑to‑event efficacy conclusions. (fda.gov) Operational actions the FDA requested are specific and time‑bound: the warning letter directs ImmunityBio to cease or take down the challenged communications where appropriate and to submit a written response addressing FDA’s concerns within 15 working days of receipt. (fda.gov) The market and legal fallout has been immediate: shares fell sharply after the letter became public and multiple law firms have announced investigations and suits tied to the promotional claims. (finance.yahoo.com)
